The aim is to investigate the effects of reducing apolipoprotein C-III in individuals with moderate hypertriglyceridaemia and elevated cardiovascular risk.
Intervention evaluated in a randomized trial with subjects at high cardiovascular risk.
Enrollment of subjects with moderate hypertriglyceridaemia.
Trial registration ID: NCT03385239.
Significant reduction in apolipoprotein C-III levels observed in intervention group compared to control.
Improvement in lipid profiles noted, indicating potential cardiovascular risk reduction.